Astronomers have produced the most detailed map yet of dark matter, revealing the invisible framework that shaped the Universe long before stars and galaxies formed. Using powerful new observations ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...

Running 17 best walking shoe deals from Hoka, Asics, and Nike — spring deals with up to 47% off Running I just found the 9 best Asics deals on Amazon — and runners will not be disappointed Running ...

The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

Anchor your business to a stubborn, real-world problem customers cannot ignore. Replace hustle with systems that standardize decisions, data flow and accountability. Ambition isn’t what holds ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...

Just two of the nine shoes leading Nike’s reorganized running lineup have yet to release. Both of those come from the Structure franchise, and one has been confirmed for an early 2026 release. The ...

OpenAI announced Tuesday morning that it had completed a tumultuous corporate restructuring effort, simplifying a complex ownership web into a controlling nonprofit entity and a reimagined for-profit ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...